Invention Grant
- Patent Title: Compositions and methods for TCR reprogramming using fusion proteins
-
Application No.: US16322897Application Date: 2017-08-02
-
Publication No.: US11242376B2Publication Date: 2022-02-08
- Inventor: Patrick Baeuerle , Gregory Sieczkiewicz , Robert Hofmeister
- Applicant: TCR2 THERAPEUTICS INC.
- Applicant Address: US MA Cambridge
- Assignee: TCR2 THERAPEUTICS INC.
- Current Assignee: TCR2 THERAPEUTICS INC.
- Current Assignee Address: US MA Cambridge
- Agency: Wilson Sonsini Goodrich & Rosati
- International Application: PCT/US2017/045159 WO 20170802
- International Announcement: WO2018/026953 WO 20180208
- Main IPC: C07K16/28
- IPC: C07K16/28 ; C07K14/725 ; A61K35/17 ; C07K14/705 ; A61K35/12 ; A61K39/00
Abstract:
Provided herein are T-cell receptor (TCR) fusion proteins (TFPs), T-cells engineered to express one or more TFPs, and methods of use thereof for the treatment of diseases, including cancer.
Public/Granted literature
- US20190256571A1 COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING FUSION PROTEINS Public/Granted day:2019-08-22
Information query
